Disease · MONDO_0005203

ischemia reperfusion injury

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ischemia reperfusion injury. Diseases, record MONDO_0005203. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005203

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ischemia reperfusion injury; Open Targets
Open Targets ID: MONDO_0005203; Open Targets
Other names: ischaemia reperfusion injury, myocardial reperfusion injury; Open Targets
MeSH: D015427; MeSH
Highest stage of its drugs: Phase 3, for 3 of its 42 drugs, from ClinicalTrials.gov; Open Targets

Drugs42

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HEME ARGINATE	CHEMBL4297285	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MANNITOL	CHEMBL689	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SIMVASTATIN	CHEMBL1064	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
SODIUM NITRITE	CHEMBL93268	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS ANHYDROUS	CHEMBL269732	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DIANEXIN	CHEMBL2364643		Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 42

See all 42 drugs

Targets81

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 81

See all 81 targets

Trials40

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03470441	A Study of Acute Myocardial Infarction Using FDY-5301	Phase 2	120	2021-12-14	Acute Myocardial Infarction, STEMI	SODIUM IODIDE	Its record names the disease	ClinicalTrials.gov
NCT02134314	C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/2	70	2018-06-25	End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury	CONESTAT ALFA	Its record names the disease	ClinicalTrials.gov
NCT00995670	Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins	Not applicable	59	2015-03-17	Hyperglycemia	DEXTROSE, SEVOFLURANE, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00246740	Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting	Phase 2	56	2017-12-15	Coronary Artery Bypass Grafting, Cardiopulmonary Bypass, Reperfusion Injury	DOXYCYCLINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02314780	The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart	Phase 2	31	2021-02-15	Myocardial Ischemia	HEME ARGINATE	Its record names the disease	ClinicalTrials.gov
NCT02151877	Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass	Not applicable	24	2020-04-03	Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery	NITRIC OXIDE	Its record names the disease	ClinicalTrials.gov
NCT01388504	Nitrites in Acute Myocardial Infarction	Phase 2/3	200		Acute ST Elevation Myocardial Infarction	SODIUM NITRITE	Its record names the disease	ClinicalTrials.gov
NCT01932918	Antinociceptive Modalities on Ischemia Reperfusion Injury		142		End Stage Liver Disease, Lung Cancer	DEXMEDETOMIDINE, MORPHINE	Its record names the disease	ClinicalTrials.gov
NCT01905501	Sevoflurane Protective Effect on Ischemia-reperfusion Injury. Multicenter, Randomized Controlled Trial	Not applicable	132		Microsurgical Free Flaps	PROPOFOL, REMIFENTANIL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT05661227	Mechanism of Cardiac and Cerebral Function Injury Caused by Intraoperative Limb Ischemia-reperfusion	Not applicable	120		Ischemic Reperfusion Injury	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 40

See all 40 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Mean Number of Patients on Dialysis	0 of 35	5 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients With Serum Creatinine Reduction Ratio of < 30% From 24 to 48 Hours Post-transplant.	30 of 35	28 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Graft Survival	34 of 35	34 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Patient Survival	35 of 35	35 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: deaths from any cause	0 of 35	0 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: serious adverse events	10 of 35	10 of 35	70	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale)	15 of 34	21 of 35	69	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant.	15 of 34	21 of 35	69	NCT02134314	Trial comparisons
C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5.	29 of 34	32 of 35	69	NCT02134314	Trial comparisons
Periostat vs Placebo Oral Tablet: deaths from any cause	0 of 20	0 of 22	42	NCT00246740	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials43

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27500266	RESULT	1	PubMed
27088798	RESULT	1	PubMed
26304941	RESULT	1	PubMed
23928836	RESULT	1	PubMed
23552495	RESULT	1	PubMed
22572084	RESULT	1	PubMed
21691090	RESULT	1	PubMed
21658244	RESULT	1	PubMed
21398592	RESULT	1	PubMed
21274961	RESULT	1	PubMed

1 to 10 of 43

See all 43 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005203

GET https://conductscience.org/api/diseases/v1/MONDO_0005203/drugs?page=2

API reference For AI assistants